Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, LIC

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases


WALTHAM, Mass., Dec. 17, 2018 /PRNewswire/ -- Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an exclusive, worldwide licensing agreement with AstraZeneca PLC (NYSE: AZN) for the development and commercialization rights to a novel Tropomyosin receptor kinase (TRK) modulator, PBI-100.  Pyramid Biosciences seeks to develop the TRK modulator for a range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis.

"We are pleased that AstraZeneca, a global leader in biopharmaceuticals, has chosen our team to develop and eventually commercialize this compound," says Dr. Kollol Pal, CEO and Co-Founder of Pyramid Biosciences, Inc. "PBI-100 has the potential to offer patients living with myriad dermatological and inflammatory diseases new options for treatment."

"This agreement provides an opportunity for the development of PBI-100 in therapeutic indications outside of AstraZeneca's core focus areas," says Kumar Srinivasan, VP Scientific Partnering and Alliances, IMED Biotech Unit at AstraZeneca. "Through the agreement, Pyramid Biosciences will investigate the molecule as a potential new treatment option for patients with debilitating dermatological diseases." 

Skin disease is one of the leading causes of global disease burden, affecting millions of people worldwide.1PBI-100 is a clinically-validated TRK modulator which displays anti-itch and anti-inflammatory effects. Pyramid Biosciences will conduct further clinical testing of PBI-100 for use in selected dermatological indications beginning in 2019.  

Under the agreement, Pyramid Biosciences, Inc. licenses exclusive rights to develop and commercialize the compound globally. Financial terms of the agreement were not disclosed.

About Pyramid Biosciences Inc.

Pyramid Biosciences is dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family. By precisely and selectively modulating the actions of these fundamental cell surface receptors, we can control the key signaling pathways responsible for a patient's disease, condition or symptoms.

For more information, please visit www.pyramidbio.com

Investor Inquiries:

Jordan Leef
CBO, CFO and Co-Founder
Pyramid Biosciences, Inc.
Email: [email protected]
Phone: 781.530.4461

1Journal of the American Academy of Dermatology. Volume 76, Issue 5, Pages 958?972.e2 

SOURCE Pyramid Biosciences, Inc.


These press releases may also interest you

at 07:49
In the news release, Roborock Reports 2023 Full Year Financial Results, issued 28-Mar-2024 by Roborock over PR Newswire, we are advised by the company that in the first bullet point of "Growth across Product Categories", the USD amount should read...

at 07:48
Gold's Gym SoCal ? the original home of fitness workouts ? celebrates its 35th anniversary, marking three and a half decades of unparalleled dedication to health, wellness, and community. To coincide with the milestone, Gold's Gym SoCal is unveiling...

at 07:29
In a strategic move to address the growing talent shortage in the global construction equipment industry, XCMG Machinery (SHE:000425, "XCMG") has launched an extensive cross-training program for its employees from XCMG Global Business Headquarters....

at 07:05
Syngenta Group today announced financial results for the fourth quarter and full year 2023. Syngenta Group sales for full year 2023 were $32.2 billion, down $1.2 billion or 4 percent year-on-year (-1% CER). Full year EBITDA decreased 18 percent...

at 07:00
Scrum Ventures, a San Francisco and Tokyo-based early-stage venture capital firm, announced that NBA Champion and entrepreneur Kyle Kuzma, will join the fund as an advisor....

at 07:00
Operation HOPE announced today that "FINANCIAL LITERACY FOR ALL," the latest book by its Founder and CEO John Hope Bryant, has reached #1 on Amazon for Economics, prior to its April 16, 2024 release. From the best-selling author of "Up from Nothing,"...



News published on and distributed by: